PharmaEssentia
1165,00 NT$Variación respecto al cierre anterior: −0,43 %Variación absoluta: −5,00 NT$
Perfil de la empresa
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Descripción disponible en inglés.
Datos societarios
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- País
- Taiwán
- Sede
- No. 3, Park Street, 115, Taipei
- Cotización
- 6446 · TWSE
- Divisa
- TWD
- Sitio web
- pharmaessentia.com